OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TBRG$25.8458

TruBridge Inc

Advanced Medical Equipment & TechnologyVerified

TruBridge operates with a debt-to-equity ratio of 1.0, indicating a balanced capital structure, while its current ratio of 1.95 suggests moderate liquidity. The company's price-to-book ratio of 2.1 and price-to-tangible-book ratio of 2.1 reflect a market valuation that is slightly above book value, but its negative return on equity (-1.0%) and return on assets (-0.45%) indicate poor profitability relative to its capital base. The company's operating income of $662,000 is modest compared to its revenue of $84.1 million, and its net income is negative at -$1.85 million, signaling financial strain. The enterprise value to EBITDA ratio of 858.41 is extremely high, suggesting that the company is overvalued relative to its earnings, while the enterprise value to revenue ratio of 6.76 is in line with industry norms. TruBridge's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to sector-specific risks. The company's capital expenditures of -$5.02 million indicate a reduction in investment in long-term assets, which may affect future growth. Looking ahead, the company is expected to maintain a flat revenue trajectory, with no significant growth anticipated in the next fiscal year. Analysts have assigned a mean price target of $25.67, with a median of $26.25, suggesting limited upside potential. The company faces moderate liquidity risk due to negative free cash flow of -$601,000 and negative operating cash flow of -$2.08 million, which could constrain its ability to fund operations without external financing. While dilution risk is currently low, the company's negative net cash position after subtracting total debt raises concerns about its financial flexibility. Recent filings and transcripts have not disclosed any material events that would significantly alter the company's financial outlook, and no major strategic shifts have been reported.

30-day price · TBRG(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyTruBridge Inc
TickerTBRG.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. TruBridge Inc provides healthcare equipment and technology solutions, primarily serving the healthcare services and equipment sector.

Classification. TruBridge is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

TruBridge operates with a debt-to-equity ratio of 1.0, indicating a balanced capital structure, while its current ratio of 1.95 suggests moderate liquidity. The company's price-to-book ratio of 2.1 and price-to-tangible-book ratio of 2.1 reflect a market valuation that is slightly above book value, but its negative return on equity (-1.0%) and return on assets (-0.45%) indicate poor profitability relative to its capital base. The company's operating income of $662,000 is modest compared to its revenue of $84.1 million, and its net income is negative at -$1.85 million, signaling financial strain. The enterprise value to EBITDA ratio of 858.41 is extremely high, suggesting that the company is overvalued relative to its earnings, while the enterprise value to revenue ratio of 6.76 is in line with industry norms. TruBridge's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to sector-specific risks. The company's capital expenditures of -$5.02 million indicate a reduction in investment in long-term assets, which may affect future growth. Looking ahead, the company is expected to maintain a flat revenue trajectory, with no significant growth anticipated in the next fiscal year. Analysts have assigned a mean price target of $25.67, with a median of $26.25, suggesting limited upside potential. The company faces moderate liquidity risk due to negative free cash flow of -$601,000 and negative operating cash flow of -$2.08 million, which could constrain its ability to fund operations without external financing. While dilution risk is currently low, the company's negative net cash position after subtracting total debt raises concerns about its financial flexibility. Recent filings and transcripts have not disclosed any material events that would significantly alter the company's financial outlook, and no major strategic shifts have been reported.
Key takeaways
  • TruBridge has a balanced capital structure but faces liquidity challenges due to negative free and operating cash flows.
  • The company's profitability metrics are weak, with negative returns on equity and assets.
  • Revenue is concentrated in a single segment, increasing exposure to sector-specific risks.
  • Analysts project limited upside, with a mean price target of $25.67 and a median of $26.25.
  • The company's high EV/EBITDA ratio suggests overvaluation relative to earnings.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUnknown error in universe processing
Revenue$84.1M
Gross profit$42.4M
Operating income$662.0k
Net income-$1.9M
R&D
SG&A
D&A
SBC
Operating cash flow-$2.1M
CapEx-$5.0M
Free cash flow-$601.0k
Total assets$416.4M
Total liabilities$231.7M
Total equity$184.7M
Cash & equivalents$4.1M
Long-term debt$184.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$280.6M$24.7M$18.4M$25.0M
FY-3$326.6M$23.2M$15.9M$19.8M
FY-2$337.0M-$45.7M-$48.1M-$43.6M
FY-1$342.2M$7.9M-$20.9M-$10.5M
FY0$346.8M$20.9M$4.4M$13.5M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$383.4M$222.6M$11.4M
FY-3$431.0M$231.7M$7.0M
FY-2$434.4M$186.6M$3.8M
FY-1$395.8M$167.1M$12.3M
FY0$402.5M$178.0M$24.9M
PeriodOCFCapExFCFSBC
FY-4$47.7M-$10.3M$25.0M
FY-3$32.4M-$19.4M$19.8M
FY-2-$522.0k-$21.8M-$43.6M
FY-1$31.1M-$18.1M-$10.5M
FY0$37.0M-$17.1M$13.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$84.1M$662.0k-$1.9M-$601.0k
FQ-6$85.6M-$2.1M-$4.4M$505.0k
FQ-5$84.7M$2.8M-$9.1M-$8.0M
FQ-4$87.8M$6.6M-$5.6M-$2.4M
FQ-3$87.2M$8.2M$459.0k$2.5M
FQ-2$85.7M$3.6M$2.6M$4.5M
FQ-1$86.1M$4.1M$5.6M$8.0M
FQ0$87.8M$5.0M-$4.3M-$1.5M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$416.4M$184.7M$4.1M
FQ-6$412.3M$181.1M$7.7M
FQ-5$401.5M$172.6M$8.6M
FQ-4$395.8M$167.1M$12.3M
FQ-3$388.8M$168.5M$10.1M
FQ-2$390.2M$173.2M$12.3M
FQ-1$399.4M$180.4M$19.9M
FQ0$402.5M$178.0M$24.9M
PeriodOCFCapExFCFSBC
FQ-7-$2.1M-$5.0M-$601.0k
FQ-6$11.7M-$9.6M$505.0k
FQ-5$21.8M-$14.9M-$8.0M
FQ-4$31.1M-$18.1M-$2.4M
FQ-3$5.8M-$4.3M$2.5M
FQ-2$14.5M-$9.1M$4.5M
FQ-1$28.1M-$13.3M$8.0M
FQ0$37.0M-$17.1M-$1.5M
Valuation
Market price$25.84
Market cap$387.6M
Enterprise value$568.3M
P/E
Reported non-GAAP P/E
EV/Revenue6.8
EV/Op income858.4
EV/OCF
P/B2.1
P/Tangible book2.1
Tangible book$184.7M
Net cash-$180.7M
Current ratio1.9
Debt/Equity1.0
ROA-0.4%
ROE-1.0%
Cash conversion1.1%
CapEx/Revenue-6.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricTBRGActivity
Op margin0.8%-16.5% medp25 -174.5% · p75 8.8%above median
Net margin-2.2%-16.5% medp25 -172.4% · p75 8.4%above median
Gross margin50.4%47.4% medp25 34.2% · p75 65.3%above median
CapEx / revenue-6.0%-5.4% medp25 -12.5% · p75 -2.2%below median
Debt / equity100.0%4.3% medp25 0.0% · p75 28.0%top quartile
Observations
IR observations
Mean price target25.67 USD
Median price target26.25 USD
High price target26.25 USD
Low price target23.00 USD
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count6.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2.54 USD
Last actual EPS2.66 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-17 01:56 UTC#582554e5
Market quoteclose USD 25.71 · shares 0.01B diluted
no public URL
2026-05-17 01:56 UTC#29679c70
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 16:13 UTCJob: 743c4284